Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of acute myeloid leukemia cells

Li,Na; Jia,Xiuhong; Wang,Jianyong; Li,Youjie; Xie,Shuyang

doi:10.3892/mmr.2015.4331

Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of acute myeloid leukemia cells

Authors:
- Na Li
- Xiuhong Jia
- Jianyong Wang
- Youjie Li
- Shuyang Xie
View Affiliations

Affiliations: Department of Pediatrics, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256003, P.R. China, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: September 15, 2015 https://doi.org/10.3892/mmr.2015.4331
Pages: 6861-6866

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Homeobox genes encode transcription factors that are essential for embryonic morphogenesis and differentiation. Transcription factors containing the highly conserved homeobox motif show considerable promise as potential regulators of hematopoietic maturation events. Previous studies have suggested that the increased expression levels of homeobox (HOX)A genes was correlated with the cytogenetic findings associated with poor prognosis in acute myeloid leukemia and mixed lineage leukemia. The aim of the present study was to investigate the role of HOXA5 in leukemia. The U937 human leukemia cell line was transfected with a HOXA5‑targeted short hairpin RNA (shRNA) to determine the effects of downregulation of the HOXA5 on proliferation, apoptosis, cell cycle distribution and chemoresistance in leukemia cells. Reverse transcription‑quantitative polymerase chain reaction and western blot analyses demonstrated that the mRNA and protein expression levels of HOXA5 were markedly suppressed following transfection with an shRNA‑containing vector. Knockdown of HOXA5 significantly inhibited cell proliferation, as determined by Cell Counting kit‑8 assay. Flow cytometry revealed that reduced HOXA5 expression levels resulted in cell cycle arrest at the G1 phase, and induced apoptosis. In addition, western blot analysis demonstrated that HOXA5 knockdown increased the expression levels of caspase‑3, and reduced the expression levels of survivin in the U937 cells. Furthermore, knockdown of HOXA5 in the U937 cells enhanced their chemosensitivity to cytarabine. The results of the present study suggested that downregulation of HOXA5 by shRNA may trigger apoptosis and overcome drug resistance in leukemia cells. Therefore, HOXA5 may serve as a potential target for developing novel therapeutic strategies for leukemia.

View Figures

View References

1	Passegué E, Jamieson CH, Ailles LE and Weissman IL: Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA. 100(Suppl 1): 11842–11849. 2003. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Estey E and Döhner H: Acute myeloid leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
4	Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, et al: Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 10:4991–4997. 2004. View Article : Google Scholar : PubMed/NCBI
5	Christiansen DH, Andersen MK, Desta F and Pedersen-Bjergaard J: Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 19:2232–2240. 2005. View Article : Google Scholar : PubMed/NCBI
6	Plass C, Oakes C, Blum W and Marcucci G: Epigenetics in acute myeloid leukemia. Semin Oncol. 35:378–387. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yao K, Xing H, Yang W, Liao A, Wu B, Li Y, Zhang R and Liu Z: Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells. Tumour Biol. 35:8023–8031. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cillo C, Cantile M, Faiella A and Boncinelli E: Homeobox genes in normal and malignant cells. J Cell Physiol. 188:161–169. 2001. View Article : Google Scholar : PubMed/NCBI
9	Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R, Döhner H and Pollack JR: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 350:1605–1616. 2004. View Article : Google Scholar : PubMed/NCBI
10	Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P and Ostergaard M: Gene expression profiling of Polycomb: Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol. 81:112–122. 2008. View Article : Google Scholar : PubMed/NCBI
11	Thorsteinsdottir U, Sauvageau G and Humphries RK: Hox homeobox genes as regulators of normal and leukemic hematopoiesis. Hematol Oncol Clin North Am. 11:1221–1237. 1997. View Article : Google Scholar
12	Crooks GM, Fuller J, Petersen D, Izadi P, Malik P, Pattengale PK, Kohn DB and Gasson JC: Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Blood. 94:519–528. 1999.PubMed/NCBI
13	Lawrence HJ and Largman C: Homeobox genes in normal hematopoiesis and leukemia. Blood. 80:2445–2453. 1992.PubMed/NCBI
14	Celetti A, Barba P, Cillo C, Rotoli B, Boncinelli E and Magli MC: Characteristic patterns of HOX gene expression in different types of human leukemia. Int J Cancer. 237–244. 1993. View Article : Google Scholar : PubMed/NCBI
15	Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L, Zeng C, Baron A, Hunger SP, Varella-Garcia M, et al: Quantitative HOX expression in chromosomally defined subsets of acute myelogenousleukemia. Leukemia. 16:186–195. 2002. View Article : Google Scholar : PubMed/NCBI
16	Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD and Lander ES: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 286:531–537. 1999. View Article : Google Scholar : PubMed/NCBI
17	Shah N and Sukumar S: The hox genes and their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010. View Article : Google Scholar : PubMed/NCBI
18	Graham A, Papalopulu N and Krumlauf R: The murine and drosophila homeobox gene complexes have common features of organization and expression. Cell. 57:367–378. 1989. View Article : Google Scholar : PubMed/NCBI
19	Waltregny D, Alami Y, Clausse N, de Leval J and Castronovo V: Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate. 50:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
20	Makiyama K, Hamada J, Takada M, Murakawa K, Takahashi Y, Tada M, Tamoto E, Shindo G, Matsunaga A, Teramoto K, et al: Aberrant expression of HOX genes in human invasive breast carcinoma. Oncol Rep. 13:673–679. 2005.PubMed/NCBI
21	Abe M, Hamada J, Takahashi O, Takahashi Y, Tada M, Miyamoto M, Morikawa T, Kondo S and Moriuchi T: Disordered expression of HOX genes in human non-small cell lung cancer. Oncol Rep. 15:797–802. 2006.PubMed/NCBI
22	Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K and Sauvageau G: Overexpression of the myeloid leukemia-associated hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 99:121–129. 2002. View Article : Google Scholar : PubMed/NCBI
23	Bach C, Buhl S, Mueller D, García-Cuéllar MP, Maethner E and Slany RK: Leukemogenic transformation by HOXA cluster genes. Blood. 115:2910–2918. 2010. View Article : Google Scholar : PubMed/NCBI
24	Mulgrew NM, Kettyle LM, Ramsey JM, Cull S, Smyth LJ, Mervyn DM, Bijl JJ and Thompson A: c-Met inhibition in a HOXA9/Meis1 model of CN-AML. Dev Dyn. 243:172–181. 2014. View Article : Google Scholar
25	Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L and Zhang Y: Leukaemic transformation by CALM-AF10 involves upregulation of hoxa5 by hDOT1 L. Nat Cell Biol. 8:1017–1024. 2006. View Article : Google Scholar : PubMed/NCBI
26	Quentmeier H, Dirks WG, Macleod RA, Reinhardt J, Zaborski M and Drexler HG: Expression of HOX genes in acute leukemia cell lines with and without MLL translocations. Leuk Lymphoma. 45:567–574. 2004. View Article : Google Scholar : PubMed/NCBI
27	Deveraux QL and Reed JC: IAP family proteins-suppressors of apoptosis. Gen Dev. 13:239–252. 1999. View Article : Google Scholar
28	Karami H, Baradaran B, Esfahani A, Estiar MA, Naghavi-Behzad M, Sakhinia M and Sakhinia E: siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev. 14:7719–7724. 2013. View Article : Google Scholar
29	Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI
30	Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S and Cerni C: Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene. 22:4266–4280. 2003. View Article : Google Scholar : PubMed/NCBI
31	Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H and Sasamata M: YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol. 39:569–575. 2011.PubMed/NCBI
32	Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T and Altieri DC: Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 9:2683–2692. 2003.PubMed/NCBI